24/7 Wall St. on MSN
Price prediction: Why AbbVie’s post-Humira pivot makes it a strong buy
Quick Read AbbVie (ABBV) reported Q1 revenue of $15B, beating consensus by $280M, while Skyrizi surged 30.9% YoY to $4.48B ...
Pharmaceutical giant AbbVie said Thursday it has agreed to pay more than $10 billion to buy Waltham cancer drug maker ImmunoGen, in the largest acquisition of a Massachusetts company this year. The ...
Zacks Investment Research on MSN
ABBV stock up 5% on robust Q1 performance: Time to buy, sell or hold?
AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for ...
By Kamal Choudhury and Christy Santhosh April 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly ...
AbbVie (ABBV) stock gains as the company raised its full-year earnings outlook despite a mixed performance in Q1 2026. Read ...
(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
This drug has boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.
Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...
This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...
Optum Rx will add two more Humira biosimilars to its formulary later this summer. The pharmacy benefit manager—one of the three largest in the market—will place Boehringer Ingelheim's Cyltezo and ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...
(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results